Advances of Site-Specific Antibody Conjugations: Design and Development for ADCs and Beyond
A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Antibody Discovery and Engineering".
Deadline for manuscript submissions: 30 July 2024 | Viewed by 76
Special Issue Editor
Interests: antibody–drug conjugates; antibody glycan engineering; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antibody–drug conjugates (ADCs) are emerging as powerful precision medicines that deliver highly toxic chemotherapy agents specifically to antigen-bearing cancer cells. As one of the most powerful and successful avenues for cancer treatment, ADCs combine the advantage of high specificity of antibodies to avoid damaging effects on healthy cells and extreme potency of the cytotoxic payload to achieve cancer cell killing. The overall efficacy of an ADC is determined by the rational combination of the cell target, the antibody, the payload, the linker that connects the payload, and the bioconjugation method. The first generation of approved ADCs mainly relies on non-specific conjugation at lysine and/or hinge cysteines. This random conjugation strategy usually results in heterogeneous ADCs, which will likely affect the stability, characterization, process control and pharmacokinetic properties. To overcome the issues, site-specific conjugation strategies to generate homogeneous ADCs with tunable drug-to-antibody (DARs) ratios have been developed rapidly in recent years, which leads to more consistent quality attributes, improved pharmacokinetics, and an enhanced therapeutic index. Site-specific ADCs are likely to be the future of targeted cancer therapeutics. In this Special Issue, advances will be presented in the discovery and development of novel site-specific ADCs, including the exploration of novel conjugate chemistries, novel linker and payloads, novel target antigens and the evaluation of ADCs. Besides the preparation of ADCs, novel site-specific conjugation methods will also be applied in the generation of antibody immunoconjugates and PROTAC/ligand/antibiotic/radioisotope/siRNA/fluorophore conjugates, etc., for both therapeutic and diagnostic purposes.
Dr. Guanghui Zong
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody–drug conjugates
- site-specific conjugation
- antibody–PROTAC conjugates
- antibody–antibiotic conjugates
- small molecule–antibody conjugates
- targeted cancer therapy
- linker-payloads
- efficacy
